Patented Technology
Practical, More Effective, Clinically proven
The Rapid Nexus wound treatment system has been proven more effective to treat a variety of chronic and nonhealing wounds during our extensive clinical research.
A nanotechnology wound gel dressing formulation that has shown to be effective in chronic wound healing of non-healing and hard to heal wounds. It has shown to …
A therapeutic heating device equipped with light-emitting diodes (LEDs) that increase the local blood circulation in order to accelerate the body’s reaction to Hemastyl …
Helps the healthcare professional massage Hemastyl Rx® onto a wound’s surrounding …
Derma Firm Air-Flo is a highly comfortable and very effective breathable compression tape that keeps the Hemastyl Rx® dressing secure during the healing process. As it is made of paper material, it is hypoallergenic and can be used without fear of skin …
Derma Air-Flo is a highly comfortable and very effective breathable compression aid that secures the Hemastyl Rx® dressing, even on challenging areas. It conforms readily and stretches easily in any direction to accommodate swelling and promote …
Derma Light Tape is a gentle, secure adhesion tape that assists during Gen-ray® treatment. It covers the treated wound securely while allowing the therapeutic heating properties of Gen-Ray® to relieve minor pain and stiffness in the treatment …
Derma Firm Air-Flo is a highly comfortable and very effective breathable compression tape that keeps the Hemastyl Rx® dressing secure during the healing process. As it is made of paper material, it is hypoallergenic and can be used without fear of skin…
Derma Air-Flo is a highly comfortable and very effective breathable compression aid that secures the Hemastyl Rx® dressing, even on challenging areas. It conforms readily and stretches easily in any direction to accommodate swelling and promote…
Derma Light Tape is a gentle, secure adhesion tape that assists during Gen-ray® treatment. It covers the treated wound securely while allowing the therapeutic heating properties of Gen-Ray® to relieve minor pain and stiffness in the treatment …
Clinically Proven
Clinical Study with Hemastyl-R (n=17)
Methods: 17 patients exhibiting co-morbidities with 1 to 40 years old large chronic leg wounds including 11 infected and suggested for amputation, were treated with the Hemastyl R® anti-infective tri-nanotechnology wound healing dressing twice daily without debridement in the patients’ own home. Wound areas were measured from wound photographs using NIH ImageJ software. Wound closure rate per week was calculated from wound area measurements.
Figure 1: Percent Wound Area over Time (weeks) of 5 Representative Infected Wounds (from a study of 17 High-risk Patients, 9 with diabetes) Treated with Hemastyl-R Twice Daily
Results: 17 wounds of high risk wound patients (11 infected and suggested for amputation prior to study enrollment) were closed on average 94% in 1 to 38 weeks. Wound closure rate ranged from 2.5% to 11.6% per week. Necrosis in and around wounds and severe cyanosis surrounding wounds were cleared in early weeks of the wound management. All 11 amputations were avoided using Hemastyl Rx.
Conclusion: Rapid Nexus Hemastyl R® treatment repaired years old non-healing wounds, eliminating infection on day 1 of treatment. The Rapid Nexus Hemastyl R® is a promising technology to provide an effective wound healing solution for non-healing chronic wounds in patients with co-morbidities. Furthermore, there were no device related adverse events reported throughout the study duration, demonstrating that the benefits afforded by treatment with Hemastyl-R were achieved while presenting few risks to the patient.
Clinical Study with Hemastyl-R + LED (n=22)
Methods: 22 patients exhibiting co-morbidities with 2 to 8 years old large chronic leg wounds including 20 infected and diagnosed for amputation (6 with pus exudate), were treated with the Hemastyl R® anti-infective tri-nanotechnology wound healing dressing twice daily without debridement in the patients’ own home. Patients underwent clinician exams 3 times per week, and the wounds were subject to 15 minutes of LED light treatment every other week to modulate pain. Wound areas were measured from wound photographs using NIH ImageJ software. Wound closure rate per week was calculated from wound area measurements.
Figure 2: Percent Wound Area over Time (weeks) of 5 Representative Infected Wounds (from a study of 22 High-risk Wound Patients, 8 with diabetes) Treated with Hemastyl-R Twice Daily and treated with Gen-Ray LED every other week
Results: 22 wounds of high risk patients (20 infected and suggested for amputation prior to study enrollment, 6 of those with pus exudate) were closed on average 95.5% in 7 to 40 weeks. Necrosis in and around wounds and severe cyanosis surrounding wounds were cleared in early weeks of the wound management. All 20 amputations were avoided using Hemastyl Rx.
Conclusion: Rapid Nexus Hemastyl RR treatment repaired years old non-healing wounds, eliminating infection on day 1 and day 2 of treatment. The Rapid Nexus Hemastyl R® is a promising technology to provide an effective wound healing solution for non-healing chronic wounds in patients with co-morbidities. Furthermore, there were no device related adverse events reported throughout the study duration, demonstrating that the benefits afforded by treatment with Hemastyl-R were achieved while presenting few risks to the patient.
- All
- Acute wounds
- Chronic wounds
